Press Coverage

Generics manufacturers prevail over Hogan Lovells client MSD (JUVE-Patent)

Various generics manufacturers have won in the second instance in the dispute over supplementary protection certificates for cholesterol-lowering drug Inegy. The Higher Regional Court Düsseldorf dismissed the appeal of US originator Merck Sharp Dome (MSD) (case IDs: I-2 U 58/18 - I-2 U 64/18 and I-2 U 82/18). The various pharmaceutical companies may continue to market imitation products in Germany, using the active substance combination ezitimibe and simvastatin.

Representatives:

For MSD (in all cases)
Hogan Lovells (Düsseldorf): Miriam Gundt (lead), Andreas von Falck; associate: Lukas Sievers
Abitz & Partner (Munich): Monica Heinemann (patent attorney)

For 1 A Pharma (I-2 U 64/18), Hexal (I-2 U 58/18) and Klinge (I-2 U 82/18)
Taylor Wessing (Munich): Jan Rektorschek, Nora Wessendorf, Anja Lunze
Maiwald (Munich): Derk Vos (patent attorney)

For Mylan dura (I-2 U 63/18)
Taylor Wessing (Munich): Christoph de Coster, Verena Bertram
Ter Meer Steinmeister & Partner (Munich): Bernd Aechter (patent attorney)

For Ratiopharm (I-2 U 62/18) and AbZ Pharma (I-2 U 59/18)
Bird & Bird (Hamburg): Anne Wolters-Höhne (lead); associates: Annika Schneider (Düsseldorf), Marie-Theres Schmid (patent attorney, Munich)

For Stada (I-2 U 61/18) and Aliud (I-2 U 60/18)
Bird & Bird (Düsseldorf): Oliver Jüngst, Moritz Schroeder
Hamm & Wittkopp (Hamburg): Alexander Wittkopp (patent attorney)

Higher Regional Court Düsseldorf, 2nd Civil Senate
Thomas Kühnen (presiding judge), Thomas Fricke, Ronny Thomas

The complete Juve-Patent article can be downloaded under:
https://www.juve-patent.com/news-and-stories/cases/generics-manufacturers-prevail-over-hogan-lovells-client-msd/

Newsletter